APLS Wutah pendapatan kuartal marang kuartal apellis.com

Logo korporat perusahaan Apellis (APLS)

Apellis Pharmaceuticals (APLS) attracts investment through its leadership in treating rare pathologies and the rapid success of Syfovre. This quarterly sales growth chart visualizes this momentum, where the value 61.00 reflects the metric's balance. Stable revenue is secured by lifelong therapy and patent protection. The company is currently focusing on the global distribution of its blockbuster through licensing, having temporarily stepped away from mergers.

APLS Wutah pendapatan kuartal marang kuartal Apellis Pharmaceuticals, Inc. (04.07.2022 - 30.05.2026)

Rincian metrik lan analitis perusahaan Apellis Pharmaceuticals Inc (APLS)

Analisis umum perusahaan:APLS - Apellis Pharmaceuticals Inc
Produk seri Apellis Pharmaceuticals, Inc.

The specifics of Apellis Pharmaceuticals (APLS) require significant expenditures to maintain strict temperature controls during the transport of ophthalmological drugs, which directly impacts operating margins. The dynamics of the quarterly revenue growth index allow for the separation of random market fluctuations from sustainable market share expansion by measuring sales growth rates compared to the same period last year to verify the fundamental strength of the business.